Kornimate/medical-research-clean huggingface dataset:
co2 supplement for treatment of acute mountain sickness

Conditions: Acute Mountain Sickness; High Altitude; Inhalation; Gas

Summary: it was reported that up to 76% people who rapidly ascend to the altitude higher than 4500 m without sufficient acclimatization will have ams which often develops 6-8 hours after reaching at high altitude. ams could be improved if there is no continuous ascent although central sleep apnea may persist much longer. it has also been well documented that exercise capacity was impaired at high altitude. oxygen inhalation is the most effective treatment method, but it is impractical for outdoor activities because of the large volume required. there are some drugs such as acetazolamide, and ibuprofen for relieving ams but side effects and inconsistent treatment effect made them to be difficulty for routine use. it is noted that adding co2 might be useful for improvement of hypoxia and exercise ability and eliminating csa. there is no available device which can accurately supply constant co2 and is functionally free of dead space. we innovated a portable device with a special mask for supplement of co2 for prophylaxis and treatment of ams.

objective: to determine whether, after rapid ascent to high altitude the device could reduce the incidence and severity of ams as defined by ams scores, improve sleep quality and reduce central sleep apnea events. methods: a randomized placebo-controlled study will be performed in 36 healthy adults with no history of travelling to high altitude (\>1000m) a year before the study. subjects will be randomly and blindly given either co2 mixed with air or air alone during daytime and sleep. blood gases will be measured 30 minutes after inhalation of air or co2. sao2, heart rate, and respiratory rate will be recorded every two hours. ams (lake louise acute mountain sickness score) will be recorded before and after sleep. psg including diaphragm emg would be recorded under co2 or air. exercise time, ventilation heart rate, respiratory rate, and sao2 will be recorded and maximal load and peak ventilation will be measured during incremental cycle exercise with inhalation of co2 or ambient air.

Eligibility criteria:
inclusion criteria: 1. bmi less than 25kg/m2 2. normal lung function. 3. healthy lowlanders (\ 1000m) a year before the study. exclusion criteria: 1. insomnia, 2. moderate or severe osa based on psg at sea level (ahi\> 15 events/hr). 3. visited to an altitude \>2500 m in the preceding year. 4. currently using medicines for diabetes, hypertension et al.

Keywords: acute mountain sickness co2 inhalation central sleep apnea
study of the efficacy and safety of intravenous pamrevlumab, in hospitalized participants with acute covid-19 disease

Conditions: COVID-19

Summary: this study evaluates the efficacy and safety of intravenous (iv) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute covid-19 disease.

this is a randomized, double-blind, placebo-controlled, phase 2, proof-of-concept study to evaluate the efficacy and safety of iv pamrevlumab, a monoclonal antibody, against connective-tissue growth factor (ctgf), in participants hospitalized with acute covid-19 disease. all concomitant medications, including approved and non-approved treatments for covid-19 (such as, hydroxychloroquine or interleukin 6 \[il-6\] inhibitors), as well as supplemental oxygenation needs, will be collected and recorded. in addition, the following will be collected and recorded: documentation of severe acute respiratory syndrome coronavirus (sars-cov-2) infection, documentation of any other infection(s) prior to or during hospitalization, and whether or not aggressive care is withheld or withdrawn, including the reason for withholding or withdrawal of care (such as a do not resuscitate/do not intubate \[dnr/dni\] order or a resource limitation).

Eligibility criteria:
inclusion criteria: 1. confirmed sars-cov-2 infection 2. respiratory compromise requiring hospitalization for covid-19 disease as evidenced by at least one (or more) of the following criteria: * interstitial pneumonia on chest x-ray or high-resolution computed tomography (findings of consolidation or ground glass opacities), or * peripheral capillary oxygen saturation \< 94% on room air, or * requiring non-invasive supplemental oxygen (such as, nasal cannula, face mask) to maintain spo2 3. not requiring mechanical ventilation and/or extracorporeal membrane oxygenation (ecmo) use at time of randomization 4. not participating in another clinical trial for the treatment of covid-19 disease through day 28 exclusion criteria: 1. female participants who are pregnant or nursing 2. participation in a clinical trial with another investigational drug for covid-19 disease 3. anticipated discharge from the hospital or transfer to another hospital or long-term care facility which is not a study site within 72 hours of randomization 4. history of allergic or anaphylactic reaction to human, humanized, chimeric or murine monoclonal antibodies

Keywords: severe acute respiratory syndrome coronavirus sars-cov-2 infection
an observational study based on endometrial cancer risk screening model

Conditions: Endometrial Neoplasms

Summary: the goal of this observational study is to test the efficiency of our endometrial cancer risk screening calculator, and improve the endometrial cancer risk screening model to form a stable and reliable non-invasive auxiliary diagnostic tool with high sensitivity and specificity in healthy women.the main question it aims to answer is: ·the efficiency of our endometrial cancer risk screening calculator participants will be collected demographic information, as well as ultrasound, blood routine test and other test results, which will be entered into the endometrial cancer risk screening calculator to obtain high-risk or low-risk prediction results.


Eligibility criteria:
inclusion criteria: 1. age: 18-70; 2. the annual update of questionnaire information required by the calculator can be completed, and the gynecological examination, gynecological b-ultrasound and blood test can be evaluated once a year, and the follow-up can be at least 1 year; the patient or family members can understand the research scheme and are willing to participate in the study, and provide e-book informed consent. exclusion criteria: 1. endometrial cancer or precancerous lesions have been diagnosed; 2. previous or current malignant tumor, currently receiving radiotherapy and chemotherapy, endocrine, targeted and immunotherapy; 3. history of endometrial resection or total hysterectomy; 4. pregnant or lactating women; 5. the patient or family member could not understand the conditions and objectives of this study.
a study to determine the effects of mk0557 in obese subjects (0557-006)(completed)

Conditions: Obesity

Summary: the purpose of this study is to assess the effects of mk0557 on body weight in obese subjects.


Eligibility criteria:
inclusion criteria: * men and women between 21 and 65 years of age, willing to avoid all prescription and nonprescription medicine to alter body weight for entire study exclusion criteria: * you are or plan to become pregnant * you have smoked or used nicotine within 6 months of the study * history of abusing alcohol and/or drugs * history of a stroke, you have diabetes mellitus, you are taking medication for high blood pressure, you have had recent surgery, you have been involved in another study within 3 months of study, use of cholesterol or anti-seizure medication during the study * have participated in a weight loss program 3 months before the study or during the course of the study
optimal fluid resuscitation for trauma patients

Conditions: Trauma

Summary: the purpose of this study is to determine if the overall fluid requirements for the first 24 hours after admission will be reduced with hextend versus a standard of care crystalloid resuscitation fluid.

following severe multi-system traumatic injury, the first 24 hours of standard resuscitation fluid will be either hextend or crystalloid depending upon attending preference. no tests or interventions will be performed for research purposes. data will be collected prospectively from patient medical records and attending clinicians to monitor fluid requirements, hemodynamics and outcome.

Eligibility criteria:
inclusion criteria: * greater than or equal to 18 years old and less than 65 years old * admission with multi-system traumatic injury * admission to the intensive care unit exclusion criteria: * less than 18 or greater than 65 years old * pregnant or lactating * no fluid resuscitation

Keywords: trauma resuscitation
ventilatory constraint, breathing pattern and ventilatory responses in obese postmenopausal women

Conditions: Obesity; Postmenopausal Women

Summary: the purpose of this study was to examine the dynamic lung volumes in obese post-menopausal women (without hormone replacement therapy) during exercise and their correlations with dyspnea.

obesity-related changes in lung volumes have shown to affect breathing mechanisms. during exercise, altered breathing mechanisms increase potential for expiratory flow limitation and compromise exercise capacity. estrogen and progesterone are potent respiratory stimulants, and their effects in the physiologic regulation of breathing are down-regulated after menopause. therefore, we theorized that the combined obesity and reduced sex hormone levels after menopause work as a double jeopardy to cause mechanical ventilatory constraint which aggravates dyspnea sensation during exercise, and thus a reduction in exercise capacity. the purpose of this study was to exam the dynamic lung volumes in obese post-menopausal women (without hormone replacement therapy) during exercise and their correlations with dyspnea. from doctoral referral and advertisement, 24 obese (bmi ≧ 27 kg/m2) and 26 lean post-menopausal women were recruited for the study. pulmonary function and body composition were measured at rest. a maximal flow volume loop (mfvl) was obtained at baseline. all subjects then performed an incremental exercise test on a cycle ergometer with workload increasing 25 watts every 3 min. during exercise, at each workload, the tidal exercise fv loops were obtained and an inspiratory capacity (ic) maneuver was conducted to assess changes in end-expiratory lung volume (eelv) and end inspiratory lung volume (eilv). dyspnea and leg fatigue were assessed using the borg scale. analysis of variance with repeated measurements was used to test the significance of the mean differences between the two groups during exercise. linear regression analysis was used to determine whether changes in dynamic lung volumes during exercise were related to changes in borg scores. statistical significance was established at p\<0.05.

Eligibility criteria:
inclusion criteria: * postmenopausal women (for at least 1 year) * age below 69 y/o * not receiving hormone replacement therapy exclusion criteria: * cardiopulmonary disease * musculoskeletal disease affecting results of maximal exercise test

Keywords: obesity postmenopausal women mechanical ventilatory constraints dynamic lung volume expiratory flow limitation
study to determine if the flu vaccine increases the risk of muscle damage in participants taking drugs that block certain proteins made by some types of immune system cells

Conditions: Cancer

Summary: a retrospective, observational study conducted on cancer patients receiving a drug that blocks certain proteins made by some types of immune system cells


Eligibility criteria:
inclusion criteria: * treatment with a checkpoint inhibitor (cpi) * age greater than or equal to 18 years on date of first claim for a cpi * icd-9 or icd-10 code for a malignancy within 180 days prior to the first claim for any cpi, and * greater than or equal to 180 days of continuous pharmaceutical and medical benefit enrollment in the database prior to the first claim for any cpi exclusion criteria: * less than 18 years of age other protocol defined inclusion/exclusion criteria could apply

Keywords: influenza myositis myocarditis rhabdomyolysis checkpoint inhibitors
protein classifier for thyroid indeterminate nodules

Conditions: Thyroid Nodule

Summary: in multi-center, prospective, double-blind cohorts, pct-dia/ms protein classifier supported by artificial neural networks will be validated to classify thyroid indeterminate nodules.


Eligibility criteria:
inclusion criteria: 1. patients with aged 18 to 70 years old; 2. patients with thyroid nodules who have not been treated with drugs; 3. patients who were diagnosed as bethesda iii and iv by cytology and pathology before operation; 4. patients who underwent total / partial thyroidectomy and had histopathological reports of corresponding cellular pathological punctured nodules; 5. patients voluntarily participate in the study after informed consent. exclusion criteria: 1. patients without operation; 2. patients with insufficient fna sample size (judged by the laboratory).
chronic endometritis in patients with recurrent miscarriages or repeated implantation failures in in-vitro fertilization

Conditions: Infertility; Endometritis; Abortion, Spontaneous

Summary: chronic endometritis is a persistent inflammation of the endometrium. chronic endometritis is asymptomatic or little symptomatic. sometimes, patient with chronic endometritis can have genital bleeding, pelvic chronic pain, pain during sexual relations, persistent vaginal white loosing. the hysteroscopy can detect the presence or absence of chronic endometritis. some studies showed that the endometritis could have an impact on the embryo implantation and could explain recurrent miscarriages or repeated embryo implantation failures. the goal of this study is to evaluate the frequency of the chronic endometritis in patients with recurrent miscarriages or repeated embryo implantation failures


Eligibility criteria:
inclusion criteria: group repeated miscarriages * women aged 18 to 43 years * ≥ 2 miscarriages before 14 weeks of gestation * genetic (karyotype x2), thrombophilic and endocrine assessment should be completed group of implantation failure in in-vitro fertilization * women aged 18 to 45 years * absence of pregnancy after 3 good quality embryos transferred in women under 35 years and 4 embryos in the 35 years and over. exclusion criteria: * positive pregnancy test * unexplained bleeding * incomplete miscarriage assessment * uterine malformation * antibiotic treatment during or within one month prior to the biopsy

Keywords: in vitro fertilization hysteroscopy endometrial biopsy
biomarkers to detect anal intraepithelial neoplasia in thai men who have sex with men

Conditions: Anal Intraepithelial Neoplasia

Summary: the goals of this application are to assess the usefulness of biomarkers, including p16 proteins, minichromosome maintenance (mcm) proteins, high-risk human papillomavirus (hpv) types, and e6 and e7 mrna/oncoproteins, as adjunct tools to anal pap smear in identifying hgain and to study the impact of hiv infection on the characteristics of anal cytology (by anal pap smear) and biomarkers. to fulfill these goals, in addition to routine practice, it will be necessary to follow 450 msm (315 hiv-positives and 135 hiv-negatives) over 60 months, and perform hra and biomarkers on all clients at baseline and every 12 months. information from this study would inform ain screening and follow up approaches in hiv-positive and hiv-negative msm in both resource-limited and resource-rich settings.

the goals of this application are to assess the usefulness of biomarkers, including p16 proteins, mcm proteins, high-risk hpv types, and e6 and e7 mrna/oncoproteins, as adjunct tools to anal pap smear in identifying hgain and to study the impact of hiv infection on the characteristics of anal cytology (by anal pap smear) and biomarkers. to fulfill these goals, in addition to routine practice, it will be necessary to follow 450 msm (315 hiv-positives and 135 hiv-negatives) over 60 months, and perform hra and biomarkers on all clients at baseline and every 12 months. information from this study would inform ain screening and follow up approaches in hiv-positive and hiv-negative msm in both resource-limited and resource-rich settings.

Eligibility criteria:
inclusion criteria: * msm with hiv negative * msm with hiv positive

Keywords: histological hgain detected biomarkers msm population hpv subtypes ain study hiv-positive and hiv-negative msm anal cytology and biomarkers likelihood of ain development at month 12 and yearly thereafter
a phase i clinical study to evaluate the safety, tolerability, and efficacy of lcar-m23, a car-t cell therapy targeting msln in patients with relapsed and refractory epithelial ovarian cancer

Conditions: Epithelial Ovarian Cancer

Summary: this study is a prospective, single-arm, open-label, single-dose dose finding and extension study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy profiles of the lcar-m23 car-t cell therapy in subjects with relapsed and refractory epithelial ovarian cancer after prior adequate standard of care.


Eligibility criteria:
inclusion criteria: 1. the subjects have been fully informed of the possible risks and benefits of participating in this study and have voluntarily signed the informed consent form (icf) 2. age: 18-70 years (including 18 and 70 years) 3. female subjects with histologically or cytologically confirmed advanced epithelial ovarian cancer including fallopian tube and primary peritoneal cancers 4. mesothelin (msln) positive 5. prior adequate standard of care, treatment failure or intolerance. 6. imaging shows an evaluable tumor lesion 7. ecog 0-1 8. expected survival ≥ 3 months exclusion criteria: 1. patients who have received the following anti-tumor treatments prior to apheresis: * cytotoxic therapy within 14 days * small molecule targeted therapy within 14 days or at least 5 half-lives, whichever is shorter * therapy with monoclonal antibody within 21 days * immunomodulatory therapy within 7 days * radiotherapy within 14 days and endocrine therapy within 14 days (including tamoxifen, aromatase inhibitor, high-potency progesterone and gonadotropin-releasing hormone analogue, etc.) 2. previously treated with car-t/tcr-t cell therapy against any target or other cell therapies or therapeutic tumor vaccine 3. previously treated with any msln-targeted therapy 4. brain metastases with central nervous system symptoms 5. pregnant or lactating women 6. any condition in which, in the opinion of the investigator, the subject is ineligible for participation in the study

Keywords: epithelial ovarian cancer
effects of treadmill gait training with loading in individuals with stroke

Conditions: Stroke; Gait Disorders, Neurologic

Summary: the purpose of this study is to determine whether the add load on non-paretic lower limb of individuals that suffer a stroke, while walking on a treadmill, is effective for restore gait symmetry of these individuals, in a subacute phase of stroke.

this is a randomized and blinded clinical trial, in which participants are being randomly divided into experimental group and control group, in order to verify the effects of adding load on gait symmetry after stroke. 40 individuals will participate, and the calculation of sample size was performed from the ratio variable symmetry of swing time, based on previous study. whereas about 15% of individuals could give up to participate in the study during their course (dropout rate), we determined a number of 20 participants in each group.

Eligibility criteria:
inclusion criteria: * first episode of stroke (ischemic or hemorrhagic) which determined unilateral hemiparesis * time of lesion less one year * able to walk independently by 10 feet on flat surface without the use of assistive devices * gait speed less than 0.8 m / s * ability to understand and obey simple commands exclusion criteria: * instability of cardiac conditions * adverse clinical conditions affecting balance and / or gait * pain and / or severe discomfort that impede the realization of the proposed activities * decompensation in systemic blood pressure, with the systolic and diastolic values above 200 mmhg and 110 mmhg, respectively, before and / or after training * submaximal heart rate above the allowed values during training

Keywords: stroke gait rehabilitation
use of non-ablative vaginal erbium yag laser for the treatment of prolapse

Conditions: Prolapse

Summary: this is a single center, investigator initiated study, sponsored by the uz leuven, leuven, belgium; comparing laser treatment to pelvic floor exercises (pfe). women with symptomatic prolapse (grade ii-iv) who seek for a conservative treatment, with no history of previous pop-surgery will be randomised to either the laser-arm or the pfe-arm. there are 3 visits where vaginal application of laser will be performed, with a 4-weeks interval. each application lasts around 15 minutes. the vaginal laser procedure will be performed in an outpatient setting, not requiring any specific preparation, analgesia or anesthesia, by one of two experienced operators. the primary objective is to evaluate the effects of vel treatment for reduction of prolapse symptoms and as a secondary outcome objective measurements. these endpoints are in line with the recommendations by durnea et al., as being the most relevant and patient centered outcomes. the second goals are to register adverse events and to determine for how long the effects of laser are sustained, with a maximum of two years. to do so, the investigators will measure long term satisfaction with, and the longevity of the effect (measured by the need for repeat or alternative therapy) of laser therapy. duration of follow-up per patient: max 27 months


Eligibility criteria:
inclusion criteria: * the presence of pop symptoms * diagnosis of cystocele or rectocele of grade ii to iv according to the pop-q system, leading the prolapse (i.e. c ≤ ba/bp) * voluntary informed consent exclusion criteria: * symptoms or anatomical evidence for intussusception / rectal prolapse * leading descent of the middle compartment (c \> ba/bp) * grade iv prolapse * previous pop surgery * pregnancy or \<12 months postpartum * vaginal bleeding, injuries or infection in the treated area

Keywords: laser pelvic floor treatment
the role of resistance training in non alcoholic fatty liver disease

Conditions: NAFLD (Non-Alcoholic Fatty Liver Disease); Resistance Training

Summary: the aim of the study is to evaluate the effect of rt on clinical and metabolic parameters in patients with nafld.

background: non alcoholic fatty liver disease (nafld) is the most prevalent liver disease in developed countries with a prevalence rate of 20-30 % of adults. about 10-25% of these individuals are estimated to meet the current diagnostic criteria for non alcoholic steatohepatitis (nash) and some may progress to cirrhosis and liver failure. nafld is now recognized as the hepatic manifestation of the metabolic syndrome. recent data shows that nafld might also predict the tendency to develop diabetes mellitus and coronary artery disease. the drug of choice for nafld is yet to be found. the recommended treatment of nafld includes weight reduction and physical activity (pa), but the data of the effect of resistance training (rt) pa on nafld is scant. aim of the study: to evaluate the effect of rt on clinical and metabolic parameters in patients with nafld. study design: randomized clinical trial. patients will be randomly allocated to 2 arms (intervention and control). the intervention arm will perform rt, whereas control arm will be advised to perform home stretching. medical examination will be performed at week 0 (baseline) and at week 13 using uniform protocols.

Eligibility criteria:
inclusion criteria: * ultrasound diagnosed fatty liver. exclusion criteria: * presence of hbsag or anti-hcv antibodies (will be obtained from blood tests at the liver clinic). * patients with known diabetes treated with antidiabetic medications. * patients with known kidney disease, chd, lung disease, inflammatory bowel disease. * excessive alcohol consumption ≥ 30 g/day in men or 20 g/ day in women.